Kyle W. Sherrill
About
In The Last Decade
Kyle W. Sherrill
7 papers receiving 471 citations
Peers
Comparison fields: 5 of 62
- Molecular Biology 422
- Cardiology and Cardiovascular Medicine 97
- Cancer Research 44
- Oncology 39
- Cell Biology 39
Countries citing papers authored by Kyle W. Sherrill
This map shows the geographic impact of Kyle W. Sherrill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle W. Sherrill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle W. Sherrill more than expected).
Fields of papers citing papers by Kyle W. Sherrill
This network shows the impact of papers produced by Kyle W. Sherrill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle W. Sherrill. The network helps show where Kyle W. Sherrill may publish in the future.
Co-authorship network of co-authors of Kyle W. Sherrill
This figure shows the co-authorship network connecting the top 25 collaborators of Kyle W. Sherrill. A scholar is included among the top collaborators of Kyle W. Sherrill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle W. Sherrill. Kyle W. Sherrill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 33 | |
| 2 | 58 | |
| 3 | 124 | |
| 4 | 128 | |
| 5 | 15 | |
| 6 | Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs. | 33 |
| 7 | 89 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.